24/7 Market News Snapshot 05 December, 2024 – BioRestorative Therapies, Inc. Common Stock (NV) (NASDAQ:BRTX)

December 5, 2024

DENVER, Colo., 05 December, 2024 (247marketnews.com) – (NASDAQ:BRTX) are discussed in this article.
BioRestorative Therapies, Inc. is navigating a challenging trading environment, currently reflecting a bearish trend with a pre-market price of $1.381, down approximately 7.93% from its previous close at $1.500. The trading volume has reached 866.95K, signaling considerable selling pressure within the market. Investors are advised to monitor key support levels and volume trends closely, as ongoing bearish momentum may indicate further retracement, potentially exacerbated by negative market sentiment or recent adverse news events pertaining to the company.

Amidst these market fluctuations, BioRestorative has made significant strides in the realm of regenerative medicine. In a major advancement, the European Patent Office has granted a Notice of Allowance for the company’s innovative patent application related to its ThermoStem® platform. This allogeneic, off-the-shelf technology is targeted at metabolic diseases and includes critical methodologies for developing a non-naturally occurring three-dimensional brown adipose-derived stem cell aggregate with patent protection extending to April 29, 2040.

Lance Alstodt, CEO of BioRestorative, highlighted the importance of this patent allowance, emphasizing the transformative potential of ThermoStem®-based brown adipose-derived stem cells in reshaping treatment approaches for obesity and metabolic disorders, especially amid prevalent GLP-1 therapies. Earlier this year, the company launched a novel exosome-based biologic program aimed at obesity and has announced plans to engage with the U.S. FDA to facilitate the formal review process for its ThermoStem® therapeutic candidate.

BioRestorative is not only advancing its core clinical programs for disc/spine diseases and metabolic disorders but is also exploring licensing opportunities for its comprehensive ThermoStem® intellectual property portfolio. These endeavors signal the company’s commitment to innovation and strategic partnerships, ultimately striving to make a significant impact on the fields of metabolic and aesthetic medicine.

Related news for (BRTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.